<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03513029</url>
  </required_header>
  <id_info>
    <org_study_id>980-08694-00</org_study_id>
    <nct_id>NCT03513029</nct_id>
  </id_info>
  <brief_title>Clinical Investigation of the VytronUS Ablation System for Treatment of Symptomatic Drug-refractory Paroxysmal Atrial Fibrillation</brief_title>
  <acronym>VITAL</acronym>
  <official_title>Clinical Investigation of the VytronUS Ablation System for Treatment of Symptomatic Drug-refractory Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VytronUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VytronUS, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      VITAL is a prospective, single arm, multicenter, interventional study to evaluate the safety&#xD;
      and effectiveness of the VytronUS Ablation System (VAS) for the treatment of symptomatic&#xD;
      paroxysmal atrial fibrillation (PAF) using low intensity collimated ultrasound (LICU) for&#xD;
      imaging and ablation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing elective catheter ablation for symptomatic PAF who are refractory or&#xD;
      intolerant to at least one antiarrhythmic drug (Class I-IV) will be screened for enrollment.&#xD;
      Patients who meet the study entry criteria and sign the patient informed consent form will be&#xD;
      enrolled and treated consistent with the 2012 Heart Rhythm Society (HRS)/European Heart&#xD;
      Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS) Expert Consensus&#xD;
      Statement on Catheter and Surgical Ablation for Atrial Fibrillation. Eligible patients will&#xD;
      receive treatment with the VAS including ultrasound imaging of the left atrium and cardiac&#xD;
      ablation to electrically isolate the pulmonary veins.&#xD;
&#xD;
      Up to 100 patients will be enrolled at up to 10 sites in Europe (EU) and in the United States&#xD;
      (US).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 20, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety: Incidence of early-onset serious adverse events</measure>
    <time_frame>7 days or discharge, whichever is sooner</time_frame>
    <description>Incidence of early-onset serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Effectiveness: Acute success and chronic freedom from AF, AFL or AT</measure>
    <time_frame>12 months</time_frame>
    <description>Acute success and chronic freedom from AF, AFL or AT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety: All serious adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>All serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Study Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VytronUS Ablation System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VytronUS Ablation System</intervention_name>
    <description>Catheter Ablation for Paroxysmal Atrial Fibrillation</description>
    <arm_group_label>Study Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 75 years&#xD;
&#xD;
          -  History of symptomatic recurrent paroxysmal atrial fibrillation (PAF) in the prior&#xD;
             year, defined by:&#xD;
&#xD;
               1. Two or more symptomatic AF episodes lasting greater than 30 seconds duration that&#xD;
                  self-terminate and lasting no more than 7 continuous days. An episode of AF â‰¤ 48&#xD;
                  hours duration terminated with electrical or pharmacologic cardioversion counts&#xD;
                  as a paroxysmal atrial fibrillation episode.&#xD;
&#xD;
               2. At least one episode of paroxysmal atrial fibrillation (PAF) documented on&#xD;
                  12-lead ECG, event monitor, or telemetry monitor in the prior year&#xD;
&#xD;
          -  Paroxysmal atrial fibrillation refractory to at least one Beta Blocker, Calcium&#xD;
             Channel Blocker, or Class I or Class III anti-arrhythmic drug (AAD).&#xD;
&#xD;
          -  Subject is indicated for a pulmonary vein ablation according to society guidelines or&#xD;
             investigational site practice.&#xD;
&#xD;
          -  Subject is able and willing to give informed consent.&#xD;
&#xD;
          -  Willingness, ability, and commitment to participate in baseline and follow-up&#xD;
             evaluations for the full duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior LA ablation or surgery&#xD;
&#xD;
          -  Persistent, longstanding persistent, or permanent AF&#xD;
&#xD;
          -  AF secondary to electrolyte imbalance, thyroid disease or reversible or non-cardiac&#xD;
             cause&#xD;
&#xD;
          -  NYHA Class III or IV congestive heart failure&#xD;
&#xD;
          -  Rheumatic heart disease&#xD;
&#xD;
          -  Atrial myxoma&#xD;
&#xD;
          -  LVEF &lt;40% measured by acceptable cardiac testing (e.g. TTE, TEE)&#xD;
&#xD;
          -  Anteroposterior LA diameter &gt;5.5cm or &lt;3.5cm by TTE, CT or MRI&#xD;
&#xD;
          -  Presence of intracardiac thrombus (including a known history of thrombus) within 30&#xD;
             days prior to the index ablation procedure&#xD;
&#xD;
          -  Presence of pulmonary vein stent(s)&#xD;
&#xD;
          -  Presence of pre-existing pulmonary narrowing or pulmonary vein stenosis greater than&#xD;
             70%&#xD;
&#xD;
          -  Presence of pre-existing pericardial effusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Director Clinical Affairs</last_name>
    <phone>+1 408 730 1333</phone>
    <email>davidh@vytronus.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Na Homolce</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study coordinator</last_name>
      <email>Katerina.Mzourkova@homolka.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 27, 2018</study_first_submitted>
  <study_first_submitted_qc>April 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2018</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAF</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>ablation</keyword>
  <keyword>low intensity collimated ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

